Where is Phathom Pharmaceuticals headquartered?

Phathom Pharmaceuticals is recorded with headquarters in Florham Park, USA in NovaPharmaNews public regulatory and sponsor datasets.

Is Phathom Pharmaceuticals publicly traded?

Yes — Phathom Pharmaceuticals is listed as a public company with ticker PHAT on NYSE in SEC EDGAR-derived records.

What drugs are associated with Phathom Pharmaceuticals?

We link 1 drug profile(s) where Phathom Pharmaceuticals appears as originator or marketer in FDA or regional approval metadata.

What clinical trials is Phathom Pharmaceuticals sponsoring?

Phathom Pharmaceuticals is linked to 11 pipeline program(s) sourced from ClinicalTrials.gov and EU CTIS where sponsor names match.

What patents list Phathom Pharmaceuticals as applicant?

8 USPTO PatentsView record(s) name Phathom Pharmaceuticals or a normalized variant as applicant.

What pipeline phases does Phathom Pharmaceuticals have in our database?

Phase distribution from linked programs: phase 1: 5, phase 3: 3, approved: 2, phase 2: 1.

How many US-approved drugs are linked to Phathom Pharmaceuticals?

1 linked drug profile(s) include US approval status in openFDA-derived metadata.

Where does NovaPharmaNews source data on Phathom Pharmaceuticals?

Profiles combine SEC EDGAR (US issuers), FDA openFDA, EMA medicines data, ClinicalTrials.gov, EU CTIS, USPTO PatentsView, and regional PBS/PMDA/NMPA feeds. See /about/data-sources.

Is Phathom Pharmaceuticals data investment advice?

No. This profile is compiled from public regulatory records for professional reference only, not investment or medical advice.

Is Phathom Pharmaceuticals data investment advice?

No. This profile is compiled from public regulatory records for professional reference only, not investment or medical advice.

Phathom Pharmaceuticals Pharmaceuticals Company Profile

Name: Phathom Pharmaceuticals intelligence dataset
Creator: NovaPharmaNews
License: https://www.sec.gov/edgar.shtml

Company details

Status: Public
HQ: 100 Campus Drive, Suite 102, Florham Park, New Jersey 07932, US
Founded: 2018
Employees: 420
Programs: 11
Drugs: 5
Patents: 8

Official website ↗ All projects Drug pipeline Patents News & analysis

Quick answer

Phathom Pharmaceuticals is a pharma organization headquartered in Florham Park, USA. It trades on NYSE under ticker PHAT. Primary therapeutic focus areas include H Pylori Infection, H. Pylori Infection, Eosinophilic Esophagitis, Erosive Esophagitis, Gastroesophageal Reflux. NovaPharmaNews links 11 clinical program(s), 1 drug profile(s), and 8 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 1 (5), phase 3 (3), approved (2).

Company snapshot

Phathom Pharmaceuticals (Nasdaq: PHAT) is a biopharmaceutical company committed to transforming the treatment landscape for people suffering from gastrointestinal (GI) diseases related to acid. We are a team of highly driven pharmaceutical professionals who are passionate about our mission to address unmet needs for patients and improve their quality of life. By ensuring all voices are heard, hold

1 approved product(s) across US/EU regulatory metadata.
11 active pipeline program(s) linked via ClinicalTrials.gov.
8 US patent(s) indexed to this assignee profile.

Public regulatory, clinical, patent, and corporate records for Phathom Pharmaceuticals. Not investment advice.

Top assets

View drugs (5) View projects (11)

Lead pipeline drugs

capsule
Marketed / approved
stro-
Marketed / approved
urea
approved
urea, c-14
approved

Active clinical programs

Vonoprazan Non-Erosive Gastro-Esophageal Reflux Disease
Phase 3
Vonoprazan Erosive Esophagitis
Phase 3
Vonoprazan Helicobacter Pylori Infection
Phase 3
Vonoprazan Eosinophilic Esophagitis
Phase 2

Momentum

Proprietary activity score for Phathom Pharmaceuticals.

1 active signal

20 /100 +0 vs 30 days ago

Signal breakdown

Clinical trials 15 30d
Nova articles 0 30d
Patents filed 0 30d
FDA actions 0 30d
SEC filings 0 30d
Conference presentations 0 90d
Pipeline advances 0 30d

Competitor landscape

Therapeutic-area overlap peers from registry and pipeline signals.

Peer + 0 momentum

IRONWOOD PHARMACEUTICALS

TA overlap score 26.6

Recent activity

Latest pipeline, patent, and corporate events for Phathom Pharmaceuticals.

Jun 8, 2026 Clinical update
Vonoprazan — Phase 3
Jun 8, 2026 Clinical update
Vonoprazan — Phase 1
Jun 8, 2026 Clinical update
Vonoprazan — Phase 1
Jun 8, 2026 Clinical update
PYTEST® 14C-Urea Capsule Breath Test (at Home) — Approved
Jun 8, 2026 Clinical update
PYTEST® 14C-Urea Breath Test — Approved

View all clinical trial activity →

Quick answers

Common questions about this sponsor — for analysts and search.

What is Phathom Pharmaceuticals?

Phathom Pharmaceuticals is a pharma organization headquartered in Florham Park, USA. It trades on NYSE under ticker PHAT. Primary therapeutic focus areas include H Pylori Infection, H. Pylori Infection, Eosinophilic Esophagitis, Erosive Esophagitis, Gastroesophageal Reflux. NovaP
Is Phathom Pharmaceuticals publicly traded?

Yes. Phathom Pharmaceuticals is listed with ticker PHAT on NYSE per SEC EDGAR records linked on this profile.
What drugs does Phathom Pharmaceuticals develop or market?

We link 5 drug profile(s) where Phathom Pharmaceuticals is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/phathom-pharmaceuticals#company-drugs.
What are the latest developments for Phathom Pharmaceuticals?

In the last 12 months our linked public records show 11 trial program update(s) and 0 US patent grant(s) tied to this profile.
What therapeutic areas does Phathom Pharmaceuticals focus on?

Phathom Pharmaceuticals focuses on H Pylori Infection, H. Pylori Infection, Eosinophilic Esophagitis based on our analysis of their pipeline programs and drug development activities.

Therapeutic focus

Therapeutic area distribution

Pipeline concentration by therapeutic area from linked clinical programs.

Programs by therapeutic area

Others

Infectious Disease